ClinicalTrials.gg
CompletedNCT06006689Updated Oct 23, 2026

Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)

A Phase 2 interventional study of Qishen Yiqi Dripping Pills placebo 3 bags and Low dose Qishen Yiqi Dripping Pills 3 bags in Diabetic Kidney Disease, sponsored by Tasly Pharmaceutical Group Co., Ltd. Completed at 16 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Tasly Pharmaceutical Group Co., Ltd (part of China Resources Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

How we know

Updated Oct 23, 2026Now CompletedStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Diabetic Nephropathies with a site in China — 22 open to participants now, 30 under way, none of them phase 3. Diabetic Nephropathies · China.

Enrollment
20th of 52
228 · median 122
Started
2023
with 4 others
Phase 2
7 of 75
1 open now
Registered
47th of 75
by date

Among the 75 studies in Diabetic Nephropathies with a site in China, this one is the 20th largest by enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2023, is one of 7 in phase 2, and was the 47th registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

22 of the 75 studies in Diabetic Nephropathies with a site in China are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Diabetic Nephropathies with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and Safety of QiShen YiQi Dripping Pills in the treatment of Diabetic Kidney Disease (syndrome of Qi deficiency with blood stasis)

03

Conditions studied

  • Diabetic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Man or woman between 18-75 years-old
  • Subjects with type 2 diabetes mellitus
  • Subjects with a clinical diagnosis of diabetic kidney disease
  • ≥ 45 mL/min/1.73 m2
  • UACR ≥ 30 mg/g but ≤ 300 mg/g
  • Conformed to the TCM syndrome differentiation standard of chronic heart failure syndrome of Qi deficiency and blood stasis
  • Received Steady dose of ACEI or ARB therapy for chronic heart failure at least 2 weeks before receiving drug
  • Abide by the experimental protocol and cooperate with the data collection according to the researcher's judgment

Exclusion criteria

Exclusion Criteria:

  • Subjects with type 1 diabetes mellitus or other specific types of diabetes
  • Acute complications of diabetes such as diabetic ketoacidosis and hyperosmolar hyperglycemia occurred in the past 3 months
  • ≥8.5% or fasting blood glucose >11 mmol/L
  • Urinary sediment indicates "active" glomerulogenic hematuria
  • Subjects have been clinically confirmed cases of primary glomerular disease, secondary glomerular disease other than DKD or other systemic diseases
  • The presence of uncontrolled hypertension, systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg or Hypotension with a systolic blood pressure \<90mmHg and/or a diastolic blood pressure \<60mmHg
  • or AST> 2 times the
  • Serum potassium> the upper limit of normal
  • Patients with unstable basic treatment for lowering blood glucose and blood lipids within the past 3 months, and patients with unstable basic treatment for lowering blood pressure within the past 1 month (changing the type of drugs, such as changing the β-receptor blockers to calcium ion antagonists, etc.)
  • Take the following medications within the last 2 weeks:a. Other drugs for the treatment of DKD (Finerenone, Keluoxin capsule, Qizhi Yishen capsule, SGLT2i drugs, GLP-1 drugs, etc.), b. Calcium oxybenzenesulfonate for the treatment of diabetic retinopathy, c. Chinese patent medicine, Chinese medicine decoction, formula granule and other Chinese medicine preparations with the same composition or function indications, d. Tripterygium wilfordii related preparations, Huangkui capsule
  • Patients who need to take antiplatelet drugs, the dose was stable for less than 1 month
  • Serious diseases of other systemic systems that may affect the judgment of efficacy and safety
  • A history of alcohol or drug abuse with a combination of mental illness and poor control
  • Allergic to the experimental drug or its ingredients
  • Women who are pregnant or breastfeeding, or who have a need to have children during the trial
  • Participating in other clinical studies and taking drugs from other studies within 3 months prior to screening
  • The investigator deems that the patient is not suitable to participate in the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
228 participants (actual)

Study arms

  • Placebo comparator
    Placebo group

    Qishen Yiqi Dripping Pills placebo, 3 bags, take orally after meals, 3 times a day

    Drug: Qishen Yiqi Dripping Pills placebo 3 bags

  • Experimental
    Low dose group

    Low dose Qishen Yiqi Dripping Pills, 3 bags, take orally after meals, 3 times a day

    Drug: Low dose Qishen Yiqi Dripping Pills 3 bags

  • Experimental
    High dose group

    High dose Qishen Yiqi Dripping Pills, 3 bags, take orally after meals, 3 times a day

    Drug: High dose Qishen Yiqi Dripping Pills 3 bags

Interventions

  • DrugQishen Yiqi Dripping Pills placebo 3 bags

    Qishen Yiqi Dripping Pills placebo contain Qishen Yiqi dripping pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks

    Also known as: Placebo group

  • DrugLow dose Qishen Yiqi Dripping Pills 3 bags

    Low dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 2 bags(0.52g dripping pills per bag) and Qishen Yiqi dripping pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks

    Also known as: Low dose group

  • DrugHigh dose Qishen Yiqi Dripping Pills 3 bags

    High dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks

    Also known as: High dose group

06

What researchers measure

Primary outcomes

  1. Change in UACR(urinary albumin ⁃ to ⁃ creatinine ratio).

    Change in UACR from baseline to weeks 4, 8 and 12.

    Time frame: Baseline to weeks 4, 8 and 12

Secondary outcomes

  1. Ratio of subjects with UACR returned to normal.

    Ratio of subjects with UACR returned to normal at weeks 4, 8 and 12.

    Time frame: Baseline to weeks 4, 8 and 12

  2. Ratio of subjects with UACR decrease of more than 30% from baseline.

    Ratio of subjects with UACR decrease of more than 30% from baseline at weeks 4, 8 and 12.

    Time frame: Baseline to weeks 4, 8 and 12

  3. Ratio of subjects from microalbuminuria stage to macroalbuminuria

    Ratio of subjects from microalbuminuria stage to macroalbuminuria at weeks 4, 8 and 12.

    Time frame: Baseline to weeks 4, 8 and 12

  4. Change in eGFR(estimated glomerular filtration rate).

    Change in eGFR from baseline to weeks 4, 8 and 12.

    Time frame: Baseline to weeks 4, 8 and 12

  5. Change in Traditional Chinese Medicine Syndrome Score

    Change in Traditional Chinese Medicine Syndrome Score from baseline to weeks 4, 8 and 12. There were 9 clinical primary symptoms, 7 clinical secondary symptoms, tongue picture and pulse condition evaluated as TCM symptoms, which was defined as TCM syndrome score. The standard of TCM primary symptoms and secondary symptoms scored as without 0, light 2, medium 4, heavy 6 points. Tongue picture and pulse condition did not count.

    Time frame: Baseline to weeks 4, 8 and 12

  6. TCM syndrome

    Number and ratio of subjects with Clinical recovery, obvious effect, effective or ineffective in curative effect of TCM syndrome at weeks 4, 8 and 12.

    Time frame: Baseline to weeks 4, 8 and 12

Other outcomes

  1. Change in β2-MG.

    Change in β2-MG from baseline to weeks 4, 8 and 12.

    Time frame: Baseline to weeks 4, 8 and 12

  2. Change in Cys-C.

    Change in Cys-C from baseline to weeks 4, 8 and 12.

    Time frame: Baseline to weeks 4, 8 and 12

  3. Change in PCX.

    Change in PCX from baseline to week 12.

    Time frame: Baseline to week 12

  4. Change in MCP-1.

    Change in MCP-1 from baseline to week 12.

    Time frame: Baseline to week 12

07

Study locations

16 sites
  • Dongzhimen Hospital of Beijing University of Chinese Medicine
    Beijing, Beijing Municipality, China
  • Xiyuan Hospital of China Academy of Chinese Medical Sciences
    Beijing, Beijing Municipality, China
  • The Affiliated TCM Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • Hebei Province Hospital of Traditional Chinese Medicine
    Shijiazhuang, Hebei, China
  • Heilongjiang Academy of Traditional Chinese Medicine (Heilongjiang Provincial Hospital of Traditional Chinese Medicine)
    Harbin, Heilongjiang, China
  • Kaifeng Hospital of Traditional Chinese Medicine
    Kaifeng, Henan, China
  • Luoyang Third People's Hospital
    Luoyang, Henan, China
  • Sanmenxia Central Hospital
    Sanmenxia, Henan, China
  • The First Hospital of Hunan University of Chinese Medicine
    Changsha, Hunan, China
  • Shananxi Province Hospital of Traditional Chinese Medicine
    Xi'an, Shananxi, China
  • Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine
    Shanghai, Shanghai Municipality, China
  • Shanghai Sixth People's Hospital
    Shanghai, Shanghai Municipality, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
  • First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
    Tianjin, Tianjin Municipality, China
  • Hangzhou hospital of traditional Chinese medicine
    Hangzhou, Zhejiang, China
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Apr 2025, 19 months.

Of 32 industry-sponsored phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 19 months is close to that.

Counting every sponsor, half of 52 studies reached it within 21 months; a quarter within 13 and three quarters within 31.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Sep 2025 → Apr 2025 and completion Sep 2025 → Apr 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2023
First posted
Aug 23, 2023
StartActual
Sep 15, 2023
Primary completionActual
Apr 16, 2025was Sep 2025
CompletionActual
Apr 16, 2025was Sep 2025
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 23, 2026
Sites
6 sites added, 6 sites removed
Show 6 added (6 China)
  • Dongzhimen Hospital of Beijing University of Chinese Medicine · Beijing, China
  • Xiyuan Hospital of China Academy of Chinese Medical Sciences · Beijing, China
  • Heilongjiang Academy of Traditional Chinese Medicine (Heilongjiang Provincial Hospital of Traditional Chinese Medicine) · Harbin, China
  • Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine · Shanghai, China
  • Shanghai Sixth People's Hospital · Shanghai, China
  • First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Tianjin, China
Show 6 removed
  • Dongzhimen Hospital of Beijing University of Chinese Medicine · Beijing, China
  • Xiyuan Hospital of China Academy of Chinese Medical Sciences · Beijing, China
  • Heilongjiang Academy of Traditional Chinese Medicine (Heilongjiang Provincial Hospital of Traditional Chinese Medicine) · Ha'erbin, China
  • Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine · Shanghai, China
  • Shanghai Sixth People's Hospital · Shanghai, China
  • First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Tianjin, China
Oct 23, 2026
Start date
Sep 4, 2023→Sep 15, 2023
Oct 23, 2026
Primary completion
Sep 1, 2025→Apr 16, 2025 (actual)
Oct 23, 2026
Study completion
Sep 1, 2025→Apr 16, 2025 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Completed
    6 sites added, 6 sites removed
    Show 6 added (6 China)
    • Dongzhimen Hospital of Beijing University of Chinese Medicine · Beijing, China
    • Xiyuan Hospital of China Academy of Chinese Medical Sciences · Beijing, China
    • Heilongjiang Academy of Traditional Chinese Medicine (Heilongjiang Provincial Hospital of Traditional Chinese Medicine) · Harbin, China
    • Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine · Shanghai, China
    • Shanghai Sixth People's Hospital · Shanghai, China
    • First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Tianjin, China
    Show 6 removed
    • Dongzhimen Hospital of Beijing University of Chinese Medicine · Beijing, China
    • Xiyuan Hospital of China Academy of Chinese Medical Sciences · Beijing, China
    • Heilongjiang Academy of Traditional Chinese Medicine (Heilongjiang Provincial Hospital of Traditional Chinese Medicine) · Ha'erbin, China
    • Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine · Shanghai, China
    • Shanghai Sixth People's Hospital · Shanghai, China
    • First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Tianjin, China
    Start date Sep 4, 2023→Sep 15, 2023
    Primary completion Sep 1, 2025→Apr 16, 2025 (now actual)
    Study completion Sep 1, 2025→Apr 16, 2025 (now actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06006689
Responsible party
Sponsor
First posted
Aug 23, 2023
Start date
Sep 15, 2023
Primary completion
Apr 16, 2025
Completion
Apr 16, 2025
Last update
Oct 23, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion